New treatment possibilities for opioid-induced bowel dysfunction

Pain

Volumn 154, Issue 9, 2013, Pages 1491-1492

  Leppert, Wojciech ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

17 METHYLNALTREXONE; LAXATIVE; NALOXEGOL; OPIATE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ANOREXIA; BLOATING; CLINICAL PRACTICE; CONSTIPATION; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FECES IMPACTION; FLATULENCE; GASTROESOPHAGEAL REFLUX; HARD FECES; HUMAN; NAUSEA; NAUSEA AND VOMITING; NOTE; OPIOID INDUCED CONSTIPATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; XEROSTOMIA;

CONSTIPATION; FEMALE; HUMANS; MALE; NALOXONE; NARCOTIC ANTAGONISTS;

EID: 84881650946     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2013.06.010     Document Type: Editorial

References (12)

1. S.H. Ahmedzai, F. Nauck, G. Bar-Sela, B. Bosse, P. Leyendecker, and M. Hopp A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain Palliat Med 26 2012 50 60
2. T.J. Bell, S.J. Panchal, C. Miaskowski, S.C. Bolge, T. Milanova, and R. Williamson The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1) Pain Med 10 2009 35 42
3. C. Brock, S.S. Olesen, A.E. Olesen, J.B. Frøkjaer, T. Andresen, and A.M. Drewes Opioid-induced bowel dysfunction. Pathophysiology and management Drugs 72 2012 1847 1865
4. A. Corken, L. Green, P. Greene, and M. Avigan Methylnaltrexone and gastrointestinal perforation J Pain Symptom Manage 40 2010 e1 e3
5. L. Diego, R. Atayee, P. Helmons, G. Hsiao, and C.F. von Gunten Novel opioid antagonists for opioid-induced bowel dysfunction Expert Opin Investig Drugs 20 2011 1047 1056
6. P.J. Larkin, N.P. Sykes, C. Centeno, J.E. Ellershaw, F. Elsner, B. Eugene, J.R.G. Gootjes, M. Nabal, A. Noguera, C. Ripamonti, F. Zucco, W.W.A. Zuurmond, and on behalf of the European Consensus Group on Constipation in Palliative Care The management of constipation in palliative care: clinical practice recommendations Palliat Med 22 2008 796 807
7. W. Leppert The role of opioid receptor antagonists in the treatment of opioid-induced constipation - a review Adv Ther 27 2010 714 730
8. W. Leppert The role of oxycodone/naloxone in chronic pain management Wspolcz Onkol 17 2013 128 133
9. S. Mercadante, and A. Giarratano Combined oral pronged-release oxycodone and naloxone in chronic pain management Expert Opin Investig Drugs 22 2013 161 166
10. G. Rosti, A. Gatti, A. Costantini, A.F. Sabato, and F. Zucco Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment Eur Rev Med Pharmacol Sci 14 2010 1045 1050
11. N. Slatkin, J. Thomas, A.G. Lipman, G. Wilson, M.L. Boatwright, C. Wellman, D.S. Zhukovsky, R. Stephenson, R. Portenoy, N. Stambler, and R. Israel Methylnaltrexone for treatment of opioid-induced constipation in advanced illness patients J Support Oncol 7 2009 39 46
12. L. Webster, S. Dhar, M. Eldon, L. Masuoka, J. Lappalainen, and M. Sostek A Phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation PAIN® 154 2013 1542 1550